OncoGynecologyNews.net

OncoGynecology Xagena

Xagena Mappa
Medical Meeting
Neurobase.it
Gastrobase.it

Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy ( Trastuzumab [ Herceptin ] and Lapatinib [ Tykerb ] ) ...


Metastatic leiomyosarcomas of uterine or soft-tissue origin have poor prognosis and moderate chemosensitivity. Trabectedin has shown activity in pretreated leiomyosarcoma. Researchers did a single-g ...


Mammography screening may be effective in reducing breast cancer mortality in certain populations, but it can pose harm to women who participate. The limitations are best described as false-positives ...


The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin ) plus chemotherapy increases the pathologic complete remission ( pCR ) rate comp ...


Alopecia is a common side-effect of chemotherapy and affects quality of life of cancer patients. Some patients and physicians believe that alopecia could be a surrogate marker for response to chemot ...


For a woman in the United States, the average lifetime risk of breast cancer is about 12.3%; the 10-year risks of invasive breast cancer at ages 40, 50, and 60 years are 1.5%, 2.3%, and 3.5% respectiv ...


The International Breast Cancer Study Group ( IBCSG ) has presented results of the randomized phase III SOFT trial at the 2014 San Antonio Breast Cancer Symposium. Suppression of Ovarian Function Tri ...


Due to the lack of prospective randomized data for the management of liver metastases from breast cancer, and the existence of several locoregional techniques, local therapy of liver metastases should ...


As predicted by their DNA-damaging mechanism of action, Platinum compounds are expected to be particularly active in tumours deficient of mechanisms responsible for DNA damage repair, e.g. those witho ...


LABC ( Locally advanced breast cancer ) occurs at first presentation in about one-fifth of breast cancer patients worldwide, with lower incidence in countries with established screening programmes but ...


A new breast cancer vaccine candidate, ( GP2 ), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it ...


Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. Researchers have assessed the efficacy and safety of the aroma ...


Results from the phase III clinical trial of the investigational drug PB272 ( Neratinib ) for the extended adjuvant treatment of breast cancer ( ExteNET Trial ). The ExteNET trial is a double-blind, ...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. A stud ...


A retrospective analysis has compared the survival rates of women with BRCA associated breast cancer who did and did not undergo mastectomy of the contralateral breast. Participants were 390 women ...